Chugai Pharmaceutical Co., Ltd.
4519.TDrugs in Pipeline
19
Phase 3 Programs
13
Upcoming Catalysts
1
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
peginterferon alfa-2a
Chronic Hepatitis C
R744
Hemodialysis Patients
MRA(Tocilizumab)
Systemic Juvenile Idiopathic Arthritis
epoetin beta
Anemia
recombinant human erythropoietin
Chemotherapy Induced Anemia
BO-653
Graft Occlusion, Vascular
MRA (Tocilizumab)
Rheumatoid Arthritis
ibandronic acid 0.5mg
Primary Osteoporosis
MTX
Rheumatoid Arthritis
ED-71
Osteoporosis
Tocilizumab + methotrexate(MTX)
Rheumatoid Arthritis (RA)
peginterferon alfa-2a 180μg
Liver Cirrhosis
Tocilizumab+Methotrexate(MTX)
Rheumatoid Arthritis
monoclonal antibody CAL
Breast Cancer
DONQ52
Celiac Disease
nemolizumab (CIM331)
Atopic Dermatitis
Paclitaxel
Metastatic Breast Cancer
GM-611
Gastroparesis
Oxaliplatin
Colorectal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
peginterferon alfa-2a | Phase 3 | Chronic Hepatitis C | - | - |
R744 | Phase 3 | Hemodialysis Patients | - | - |
MRA(Tocilizumab) | Phase 3 | Systemic Juvenile Idiopathic Arthritis | - | - |
epoetin beta | Phase 3 | Anemia | - | - |
recombinant human erythropoietin | Phase 3 | Chemotherapy Induced Anemia | - | - |
BO-653 | Phase 3 | Graft Occlusion, Vascular | - | - |
MRA (Tocilizumab) | Phase 3 | Rheumatoid Arthritis | - | - |
ibandronic acid 0.5mg | Phase 3 | Primary Osteoporosis | - | - |
MTX | Phase 3 | Rheumatoid Arthritis | - | - |
ED-71 | Phase 3 | Osteoporosis | - | - |
Tocilizumab + methotrexate(MTX) | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
peginterferon alfa-2a 180μg | Phase 3 | Liver Cirrhosis | - | - |
Tocilizumab+Methotrexate(MTX) | Phase 3 | Rheumatoid Arthritis | - | - |
monoclonal antibody CAL | Phase 2 | Breast Cancer | - | - |
DONQ52 | Phase 2 | Celiac Disease | - | - |
nemolizumab (CIM331) | Phase 2 | Atopic Dermatitis | - | - |
Paclitaxel | Phase 2 | Metastatic Breast Cancer | - | - |
GM-611 | Phase 2 | Gastroparesis | - | - |
Oxaliplatin | Phase 2 | Colorectal Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Chugai Pharmaceutical Co., Ltd.'s drug pipeline?→
CatalystAlert tracks 19 drug candidates in Chugai Pharmaceutical Co., Ltd.'s (4519.T) pipeline across Phase 3, Phase 2. Its lead program is peginterferon alfa-2a (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Chugai Pharmaceutical Co., Ltd.'s next FDA catalyst?→
Chugai Pharmaceutical Co., Ltd.'s (4519.T) next tracked catalyst is a Phase 2 expected June 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track 4519.T biotech catalysts?→
Add 4519.T to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Chugai Pharmaceutical Co., Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.